EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

MRI biomarkers of primary CNS lymphoma outcome after MATRix: real world performance

Nitin Menon, Isabelle Naylor, Emmanuel Buba, Alberto Schena, Paul S Morgan, Christopher P Fox, Stefanie Thust

Frontiers in Oncology · 25.06.2026 · 16

DOI: 10.3389/fonc.2026.1769381 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 25.06.2026. Verfasst von Nitin Menon und 6 weiteren Autor:innen. Beteiligte Einrichtung: Neuroradiology Department, Queen's Medical Centre, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Despite treatment advances, accurate prognostication for patients with newly diagnosed primary central nervous system lymphoma (PCNSL) remains unsatisfactory. This retrospective cohort study evaluated whether T1 contrast-enhanced (T1CE) tumour volume and apparent diffusion coefficient (ADC) metrics on magnetic resonance imaging (MRI) predict survival in PCNSL patients treated uniformly with MATRix chemotherapy.

Methods

Sixty-five patients underwent pre-treatment MRI with volumetric and diffusion analysis. T1CE tumour volume, ADCmean, ADCmin and normalised diffusion parameters were assessed. Survival outcomes were analysed using univariate Cox regression for overall survival (OS) and progression-free survival (PFS), including disease-specific endpoints.

Results

None of the tested imaging variables were significantly associated with OS or PFS, including T1CE tumour volume and ADC measures. Baseline T1CE and diffusion biomarkers did not predict survival in MATRix-treated PCNSL.

Discussion

These results highlight limitations of standard MRI techniques for prognostication underscoring the need for integrated multiparametric models incorporating imaging and biological data to improve outcome prediction.

Schlagwörter

Stichwörter der Autor:innen

PCNSL = primary central nervous system lymphomaPCNSL imaginglymphoma - diagnosislymphoma prognosisresponse assessment

Autor:innen und Institutionen

  • Neuroradiology Department, Queen's Medical Centre, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom.
  • School of Medicine, University of Nottingham, Nottingham, United Kingdom.
  • Department of Haematology, Nottingham University Hospital NHS Trust, Nottingham, United Kingdom.
  • Radiological Sciences, Mental Health and Neurosciences, School of Medicine, University of Nottingham, Nottingham, United Kingdom.
  • NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom.

Zitieren

APA

Menon, N., Naylor, I., Buba, E., Schena, A., Morgan, P. S., Fox, C. P., & Thust, S. (2026). MRI biomarkers of primary CNS lymphoma outcome after MATRix: real world performance. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1769381

Vancouver

Menon N, Naylor I, Buba E, Schena A, Morgan PS, Fox CP, et al. MRI biomarkers of primary CNS lymphoma outcome after MATRix: real world performance. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1769381

BibTeX
@article{Menon2026,
  author = {Menon, Nitin and Naylor, Isabelle and Buba, Emmanuel and Schena, Alberto and Morgan, Paul S and Fox, Christopher P and Thust, Stefanie},
  title = {MRI biomarkers of primary CNS lymphoma outcome after MATRix: real world performance},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1769381}
}
Kostenlos starten →